parecoxib has been researched along with thromboxane a2 in 1 studies
| Studies (parecoxib) | Trials (parecoxib) | Recent Studies (post-2010) (parecoxib) | Studies (thromboxane a2) | Trials (thromboxane a2) | Recent Studies (post-2010) (thromboxane a2) |
|---|---|---|---|---|---|
| 436 | 186 | 229 | 5,617 | 224 | 429 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Araujo, M; Welch, WJ | 1 |
1 other study(ies) available for parecoxib and thromboxane a2
| Article | Year |
|---|---|
Cyclooxygenase 2 inhibition suppresses tubuloglomerular feedback: roles of thromboxane receptors and nitric oxide.
Topics: Animals; Arginine; Bridged Bicyclo Compounds, Heterocyclic; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Fatty Acids, Unsaturated; Feedback, Physiological; Hydrazines; Isoxazoles; Kidney Glomerulus; Kidney Tubules; Male; Membrane Proteins; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptors, Thromboxane; Thromboxane A2; Vasoconstriction | 2009 |